Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders

Core Points - The Ademi Firm is investigating Nevro for potential breaches of fiduciary duty and other legal violations related to its transaction with Globus Medical [1] - Nevro stockholders are set to receive $5.85 per share, amounting to a total equity value of approximately$250 million [2] - The transaction agreement imposes significant penalties on Nevro for accepting competing bids, raising concerns about the board's fulfillment of fiduciary duties to shareholders [3]